Physician profile
Thomas Lewis
NPI 1578776209
$5,252.57
in general payments reported to CMS, 2019-2025
25 companies · $16.35 in 2025
The $16.35 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,094 · 2020: $553 · 2021: $1,016 · 2022: $1,782 · 2023: $552 · 2024: $238 · 2025: $16.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $807.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,673.64 | 2019-2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $776.31 | 2019-2023 | |
| Pfizer INC. | $634.32 | 2019-2024 | |
| Alexion Pharmaceuticals, INC. | $368.46 | 2019-2023 | Soliris |
| E.R. Squibb & Sons, L.L.C. | $275.57 | 2019-2024 | Eliquis |
| Abbott Laboratories | $255.04 | 2019-2022 | |
| Gilead Sciences, INC. | $204.58 | 2021-2024 | Veklury |
| Inari Medical, INC. | $155.38 | 2021-2022 | |
| Boston Scientific Corporation | $151.21 | 2021-2022 | |
| Lilly USA, LLC | $130.45 | 2024-2025 | Zepbound, Mounjaro |
| Cvrx, INC. | $130.00 | 2022 | |
| Merck Sharp & Dohme LLC | $95.15 | 2019-2020 | |
| Melinta Therapeutics, LLC | $63.17 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $62.99 | 2020-2022 | |
| Ferring Pharmaceuticals INC. | $49.38 | 2023 | Rebyota |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $39.10 | 2020 | |
| Impulse Dynamics (USA) INC. | $32.56 | 2022 | |
| Abbvie INC. | $29.04 | 2021 | |
| Biomerieux INC | $22.21 | 2023 | |
| Novo Nordisk INC | $22.14 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.52 | 2021 | |
| Galderma Laboratories, L.P. | $17.86 | 2023 | |
| Chiesi USA, INC. | $17.07 | 2023 | Cleviprex |
| Allergan, INC. | $13.86 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.56 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lewis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.